Ad Copy
It’s not just any heart valve, it’s proven for women.‡1 Learn more and consult with a heart team to see if Medtronic TAVR is right for you: www.TAVRforWomen.com
Risk Info: https://bit.ly/4fW0OB1
† TAVR = Transcatheter Aortic Valve Replacement
‡ Based on the 1 year follow-up results from the SMART clinical trial which showed differences in valve performance¶ for Evolut compared to SAPIEN* and no differences in safety outcomes. SMART primarily studied small annulus patients, predominantly women.1 Additional clinical trials on women, regardless of their annulus size, have shown comparable mortality rates in women and men treated with TAVR2 and lower mortality rates for women treated with TAVR compared to women treated with surgical valve replacement3 at 1 year after the procedure.
§ Medtronic TAVR is indicated to treat patients who have been diagnosed with symptomatic severe aortic stenosis.
¶ Valve performance is as defined as freedom from bioprosthetic valve dysfunction (BVD) through 12 months. BVD is defined as a composite
including any of the following: hemodynamic structural valve dysfunction (mean gradient ≥ 20 mmHg), non-structural valve dysfunction
1. Tchétché D, Mehran R, Blackman DJ, et al. Transcatheter Aortic Valve Implantation by Valve Type in Women With Small Annuli: Results From the SMART Randomized Clinical Trial. JAMA Cardiol. Published online October 9, 2024
2. Forrest, J.K., et al., Transcatheter Aortic Valve Replacement in Women Versus Men (from the US CoreValve Trials). Am J Cardiol, 2016. 118(3): p. 396-402.
3. Skelding, K.A., et al., Transcatheter Aortic Valve Replacement Versus Surgery in Women at High Risk for Surgical Aortic Valve Replacement (from the CoreValve US High Risk Pivotal Trial). Am J Cardiol, 2016. 118(4): p. 560-6.
